Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 10:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Respimat Clear all
Completed Phase 3 Interventional Results available

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II

NCT01172821
View directory record Official record
Conditions
Asthma
Interventions
placebo, tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Los Angeles, California • Stockton, California • Centennial, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Sep 4, 2026, 10:42 AM EDT
Terminated Phase 2 Interventional Results available

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)

NCT01397201
View directory record Official record
Conditions
Asthma
Interventions
Placebo, BI 54903, Fluticasone propionate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
41
States / cities
Fountain Valley, California • Fullerton, California • Huntington Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Sep 4, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)

NCT00400153
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Atrovent Respimat (20 mcg), COMBIVENT MDI (36/206 mcg), Combivent Respimat (20 mcg/100 mcg), Placebo via corresponding inhaler for blinding purposes
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
87
States / cities
Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 74 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2014 · Synced Sep 4, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma

NCT00467740
View directory record Official record
Conditions
Asthma
Interventions
BI 1744 CL
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
10
States / cities
Lakewood, California • Los Angeles, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Sep 4, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00720499
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BI 1744 CL plus tiotropium bromide, Respimat® Inhaler
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
5
States / cities
Clearwater, Florida • Tampa, Florida • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2015 · Synced Sep 4, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)

NCT00696020
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BI 1744 CL/tiotropium bromide fixed dose combination, tiotropium bromide, Respimat® Inhaler
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
22
States / cities
Riverside, California • San Diego, California • Wheat Ridge, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2015 · Synced Sep 4, 2026, 10:42 AM EDT
Completed Phase 2 Interventional

Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

NCT04780984
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tiotropium bromide inhalation solution, Placebo
Drug
Lead sponsor
Nephron Pharmaceuticals Corporation
Industry
Eligibility
40 Years to 80 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Rock Hill, South Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2021 · Synced Sep 4, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

NCT01696058
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Placebo matching Olodaterol, Olodaterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
94
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 82 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Sep 4, 2026, 10:42 AM EDT
Terminated Phase 2 Interventional Results available

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).

NCT01396278
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Fluticasone propionate, BI 54903
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
37
States / cities
Fountain Valley, California • Fullerton, California • Long Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Sep 4, 2026, 10:42 AM EDT
Terminated Phase 2 Interventional Results available

Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy

NCT01397162
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate, Placebo, BI 54903
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
41
States / cities
Fountain Valley, California • Huntington Beach, California • Long Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Sep 4, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma

NCT01634113
View directory record Official record
Conditions
Asthma
Interventions
tiotropium-bromide, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
1 Year to 5 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Columbia, Missouri • Oklahoma City, Oklahoma • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Sep 4, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

Tiotropium / Respimat One Year Study in COPD.

NCT00387088
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Respimat, Tiotropium
Device · Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
3,991 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
57
States / cities
Birmingham, Alabama • Mobile, Alabama • Berkeley, California + 48 more
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Sep 4, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I

NCT01172808
View directory record Official record
Conditions
Asthma
Interventions
Placebo, tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,071 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
21
States / cities
Huntington Beach, California • Mission Viejo, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Sep 4, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)

NCT00776984
View directory record Official record
Conditions
Asthma
Interventions
tiotropium 5mcg/day, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
18
States / cities
Fountain Valley, California • Fresno, California • Stockton, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Sep 4, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.

NCT00528996
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BEA 2180 BR, Tiotropium Bromide, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 100 Years
Enrollment
2,080 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
56
States / cities
Jasper, Alabama • Mobile, Alabama • Berkeley, California + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Sep 4, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

NCT01694771
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Placebo matching Olodaterol, Olodaterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
90
States / cities
Florence, Alabama • Jasper, Alabama • Phoenix, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Sep 4, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis

NCT00737100
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Placebo Respimat, Tiotropium bromide 5 mcg, tiotropium bromide-low dose-2.5mcg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
Not listed
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
26
States / cities
Tucson, Arizona • San Diego, California • Jacksonville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Sep 4, 2026, 10:42 AM EDT
Terminated Phase 4 Interventional Results available

Ventilator Adapters for Combivent Respimat

NCT01969539
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Combivent Respimat via tee adapter, Combivent Respimat via ventilator adapter
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Danbury, Connecticut • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 4, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)

NCT00772538
View directory record Official record
Conditions
Asthma
Interventions
tiotropium 5mcg/day, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Riverside, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2014 · Synced Sep 4, 2026, 10:42 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD

NCT00239447
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, HandiHaler, Respimat SMI
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
10
States / cities
Little Rock, Arkansas • San Diego, California • San Jose, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Sep 4, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

Tiotropium / Respimat One-Year Study

NCT00168831
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium Inhalation Solution, Placebo
Drug · Other
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,007 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 4, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma

NCT01277523
View directory record Official record
Conditions
Asthma
Interventions
tiotropium high dose, placebo, tiotropium low dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 17 Years
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
Stockton, California • Normal, Illinois • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2014 · Synced Sep 4, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease

NCT01559116
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium + olodaterol, tiotropium, olodaterol, Placebo, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Jasper, Alabama • Easley, South Carolina • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Sep 4, 2026, 10:42 AM EDT
Completed Phase 4 Interventional Results available

The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

NCT03240575
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Olodaterol, Fluticasone propionate, Salmeterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
45
States / cities
Jasper, Alabama • Flagstaff, Arizona • Fullerton, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Sep 4, 2026, 10:42 AM EDT